MiR-200c sensitizes Olaparib-resistant ovarian cancer cells by targeting Neuropilin 1

MiR-200c sensitizes Olaparib-resistant ovarian cancer cells by targeting Neuropilin 1

Abstract Background Ovarian cancer (OC) is the most lethal gynecological malignancy and the second leading cause of cancer-related death in women. Treatment with PARP inhibitors (PARPi), such as Olaparib, has been recently introduced for OC patients, but resistance may occur and underlying mechanism...

Full description

Bibliographic Details
Main Authors: Enrica Vescarelli, Giulia Gerini, Francesca Megiorni, Eleni Anastasiadou, Paola Pontecorvi, Luciana Solito, Claudia De Vitis, Simona Camero, Claudia Marchetti, Rita Mancini, Pierluigi Benedetti Panici, Carlo Dominici, Ferdinando Romano, Antonio Angeloni, Cinzia Marchese, Simona Ceccarelli
Format: Article
Language:English
Published: BMC 2020-01-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
Ovarian cancer
PARP inhibitors
NRP1
miRNAs
Drug resistance
miR-200c
Online Access:https://doi.org/10.1186/s13046-019-1490-7

Similar Items

Similar Items